Iron chelator deferasirox rescued mice from Fas-induced fulminant hepatitis

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 660-667

  Sato, Tsutomu ^a   Kobune, Masayoshi ^a   Murase, Kazuyuki ^a   Kado, Yukari ^a   Okamoto, Tetsuro ^a   Tanaka, Shingo ^a   Kikuchi, Shohei ^a   Nagashima, Hiroyuki ^a   Kawano, Yutaka ^a   Takada, Kohichi ^a   Iyama, Satoshi ^a   Miyanishi, Koji ^a   Sato, Yasushi ^a   Takimoto, Rishu ^a   Kato, Junji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Deferasirox; Fas; Fulminant hepatitis; Iron; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CASPASE 3; CASPASE 8; DEFERASIROX; DEFEROXAMINE; FAS ANTIBODY; FAS LIGAND; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; FEMALE; HEMOSIDEROSIS; HEPATITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; LIVER CELL; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 79959790155     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00821.x     Document Type: Article

References (21)

1. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 2008; 38: 646-57.
2. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 2008; 14: S67-79.
3. Yeo W, Chan TC, Leung NW etal. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
4. Gotthardt D, Riediger C, Weiss KH etal. Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant 2007; 22: viii5-8.
5. Kato J, Kobune M, Kohgo Y etal. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J Clin Invest 1996; 98: 923-9.
6. Sakaida I, Kayano K, Wasaki S, Nagatomi A, Matsumura Y, Okita K. Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine. Scand J Gastroenterol 1995; 30: 61-7.
7. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989; 36: 1125-32.
8. Vichinsky E, Pakbaz Z, Onyekwere O etal. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 2008; 119: 133-41.
9. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008; 83: 398-402.
10. Okamoto T, Watanabe N, Yamauchi N etal. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res 1992; 52: 5278-81.
11. Kato J, Kobune M, Nakamura T etal. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.
12. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.
13. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ 1998; 5: 997-1000.
14. Sato T, Machida T, Takahashi S etal. Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. J Immunol 2004; 173: 285-96.
15. Scaffidi C, Fulda S, Srinivasan A etal. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
16. Rivero M, Crespo J, Fábrega E etal. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 2002; 9: 107-13.
17. Martinelli AL, Filho AB, Franco RF etal. Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. J Gastroenterol Hepatol 2004; 19: 1036-41.
18. Tandon N, Thakur V, Guptan RK, Sarin SK. Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. Br J Nutr 2000; 83: 235-9.
19. Lesnikov VA, Abbasi N, Lesnikova MP etal. Protection of human and murine hepatocytes against Fas-induced death by transferrin and iron. Apoptosis 2006; 11: 79-87.
20. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009; 100: 970-7.
21. Walter D, Schmich K, Vogel S etal. Switch from type II to I Fas/CD95 death signaling on in vitro culturing of primary hepatocytes. Hepatology 2008; 48: 1942-53.